Oramed Pharmaceuticals Inc. (ORMP)
ORMP moved a median of +0.69% 30 minutes after news, and +0.84% by the close. How ORMP actually reacts to news — the realized, point-in-time move the market made, measured across 145 labeled events over the last three years with zero look-ahead.
ORMP’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 34% | 140 |
| 30-min | +0.69% | 69% | 145 |
| 60-min | +0.46% | 65% | 145 |
| to close | +0.84% | 60% | 145 |
| Middle 50% of ORMP reactions | 0.00% to +1.37% |
|---|---|
| Median reaction (30-min) | +0.69% |
| Measured reactions | 145 |
Half of all Oramed Pharmaceuticals Inc. news events land between +0.00% and +1.37% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when ORMP moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ORMP's baseline. Nothing else.
Recent ORMP events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K ORAMED PHARMACEUTICALS For: Sep 15 | SEC filing · Form 8-K | SEC EDGAR | — | -0.21% | |
| Form 10-Q ORAMED PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.43% | +0.95% | |
| Form ARS ORAMED PHARMACEUTICALS For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.11% | +1.83% | |
| Form DEF 14A ORAMED PHARMACEUTICALS For: Sep 15 | SEC filing · Form DEF | SEC EDGAR | -0.11% | +1.83% | |
| Form DEFA14A ORAMED PHARMACEUTICALS | SEC filing · Form DEFA14A | SEC EDGAR | -0.11% | +1.83% | |
| Form 8-K ORAMED PHARMACEUTICALS For: Jun 25 | SEC filing · Form 8-K | SEC EDGAR | -4.63% | -2.95% | |
| Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet | Press release | PR Newswire | -0.84% | +4.60% | |
| Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes | Press release | PR Newswire | +2.36% | -0.53% | |
| Form 10-Q ORAMED PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.17% | +0.47% | |
| Form NT 10-Q ORAMED PHARMACEUTICALS For: Mar 31 | SEC filing · Form NT | SEC EDGAR | +0.86% | -7.34% | |
| Form 8-K ORAMED PHARMACEUTICALS For: Mar 25 | SEC filing · Form 8-K | SEC EDGAR | +1.46% | -0.88% | |
| Form 10-K ORAMED PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +2.13% | +0.61% | |
| Form 8-K ORAMED PHARMACEUTICALS For: Feb 19 | SEC filing · Form 8-K | SEC EDGAR | +0.76% | +2.48% | |
| Form 8-K ORAMED PHARMACEUTICALS For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -0.54% | -0.54% | |
| Oramed and Lifeward Announce Strategic Transaction | Press release | PR Newswire | +0.58% | -2.31% | |
| Form 8-K ORAMED PHARMACEUTICALS For: Jan 07 | SEC filing · Form 8-K | SEC EDGAR | +2.55% | +4.14% | |
| Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments | Press release | PR Newswire | +2.55% | +4.14% | |
| Form 8-K ORAMED PHARMACEUTICALS For: Dec 30 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +1.79% | |
| Form 8-K ORAMED PHARMACEUTICALS For: Dec 31 | SEC filing · Form 8-K | SEC EDGAR | -1.05% | +1.75% | |
| Form 8-A12B ORAMED PHARMACEUTICALS | SEC filing · Form 8-A12B | SEC EDGAR | +0.22% | +1.74% | |
| Form 8-K ORAMED PHARMACEUTICALS For: Nov 16 | SEC filing · Form 8-K | SEC EDGAR | +0.22% | +1.74% | |
| Form 8-K ORAMED PHARMACEUTICALS For: Nov 17 | SEC filing · Form 8-K | SEC EDGAR | +0.22% | +1.74% | |
| ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS | Press release | PR Newswire | +0.22% | +1.74% | |
| Oramed Reports Fiscal Third Quarter 2025 Financial Results | Press release | PR Newswire | +0.22% | +1.74% | |
| Form 8-K ORAMED PHARMACEUTICALS For: Oct 20 | SEC filing · Form 8-K | SEC EDGAR | -0.42% | +0.84% | |
| Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives | Press release | PR Newswire | +0.44% | +3.49% | |
| Form 8-K ORAMED PHARMACEUTICALS For: Sep 30 | SEC filing · Form 8-K | SEC EDGAR | +0.82% | +0.82% | |
| Form 8-K ORAMED PHARMACEUTICALS For: Aug 19 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +3.38% | |
| Form S-8 ORAMED PHARMACEUTICALS | SEC filing · Form S-8 | SEC EDGAR | +0.00% | +3.38% | |
| Form 10-Q ORAMED PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +4.25% | +4.00% | |
| Form 8-K ORAMED PHARMACEUTICALS For: Jul 22 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +7.98% | |
| Form 10-K/A ORAMED PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | +0.00% | |
| Form ARS ORAMED PHARMACEUTICALS For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | +0.00% | |
| Form DEF 14A ORAMED PHARMACEUTICALS For: Aug 19 | SEC filing · Form DEF | SEC EDGAR | +0.00% | +0.00% | |
| Form 8-K ORAMED PHARMACEUTICALS For: May 21 | SEC filing · Form 8-K | SEC EDGAR | +0.47% | +1.90% | |
| Form 10-Q ORAMED PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.91% | -2.27% | |
| Form 8-K ORAMED PHARMACEUTICALS For: Apr 24 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +4.48% | |
| Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical | Press release | PR Newswire | +3.07% | -1.75% | |
| Form 10-K ORAMED PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | -4.74% | |
| Oramed Pharmaceuticals Issues Letter to Shareholders | Press release | PR Newswire | -2.00% | +7.00% | |
| Form 8-K ORAMED PHARMACEUTICALS For: Feb 28 | SEC filing · Form 8-K | SEC EDGAR | -2.00% | +7.00% | |
| Form 8-K ORAMED PHARMACEUTICALS For: Feb 22 | SEC filing · Form 8-K | SEC EDGAR | -1.91% | -0.48% | |
| Form 8-K ORAMED PHARMACEUTICALS For: Feb 07 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -6.44% | |
| Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin | Press release | PR Newswire | +13.45% | +16.59% | |
| Form 8-K ORAMED PHARMACEUTICALS For: Jan 21 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.43% | |
| Form 8-K ORAMED PHARMACEUTICALS For: Jan 02 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.41% | |
| Form 8-K ORAMED PHARMACEUTICALS For: Dec 13 | SEC filing · Form 8-K | SEC EDGAR | +6.17% | +2.13% | |
| Form 10-Q ORAMED PHARMACEUTICALS For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -2.12% | |
| Form 8-K ORAMED PHARMACEUTICALS For: Oct 24 | SEC filing · Form 8-K | SEC EDGAR | +0.01% | +4.33% | |
| Form 8-K ORAMED PHARMACEUTICALS For: Oct 07 | SEC filing · Form 8-K | SEC EDGAR | — | -1.77% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ORMP section they belong to.
Where else ORMP is measured.
ORMP earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| BeyondSpring, Inc. - Ordinary Shares (BYSI) | 146 | 0.00% | 49% |
| Clearside Biomedical, Inc. (CLSD) | 145 | 0.00% | 46% |
| GlycoMimetics, Inc. (GLYC) | 144 | +0.53% | 54% |
| Mustang Bio, Inc. (MBIO) | 144 | -0.46% | 41% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Oramed Pharmaceuticals Inc.'s median reaction calculated?
Every labeled ORMP news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 145 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 69% of ORMP's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ORMP's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.